Class / Patent application number | Description | Number of patent applications / Date published |
514210900 | 3 or 4 amino acid residues in the peptide chain | 84 |
20100279955 | NOVEL LIPID TRIPEPTIDE-BASED HYDROGELATOR AND HYDROGEL - There is provided a hydrogelator that is capable of forming a hydrogel with an extremely small amount thereof over a liquid property range from acidic to alkaline, and a hydrogel having high environmental suitability, biocompatibility and biodegradability. A hydrogelator comprising a lipid peptide represented by Formula (1): | 11-04-2010 |
20100292174 | CASPASE INHIBITORS IN THE TREATMENT OF INFECTION-ASSOCIATED PRETERM DELIVERY - Apoptotic processes induced by infection of, or injury to, fetal and placental tissues have been implicated in preterm delivery. Thus, modulation of apoptotis constitutes a strategy for improving pregnancy outcome in women with intrauterine infections. Caspase inhibitors, including the pancaspase inhibitor Z-VAD-FMK, can be used to prevent apoptosis and, thus, prevent preterm delivery. Accordingly, compositions and methods comprising caspase inhibitors for prevention of preterm delivery are provided. | 11-18-2010 |
20100331265 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS - The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury. | 12-30-2010 |
20100331266 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 12-30-2010 |
20110082096 | GENE AND PATHWAY AND THEIR USE IN METHODS AND COMPOSITIONS FOR PREDICTING ONSET OR PROGRESSION OF AUTOIMMUNE AND/OR AUTOINFLAMMATORY DISEASES - Embodiments of the present invention concern methods, compositions and uses thereof, relating to at least one of vitiligo, or vitiligo-associated autoimmune/autoinflammatory disease (VAAAD). In particular embodiments, genetic variations in the NALP1 gene are of use to detect, diagnose, predict the risk of or treat at least one of vitiligo or VAAAD. In more particular embodiments, the presence of genetic variations such as single-nucleotide polymorphisms (SNPs) in NALP1 genetic region are of use to detect, diagnose or predict the risk of VAAAD. In other embodiments, inhibitors targeted to NALP1, caspase-1 or caspase-5, ASC (PYCARD), interleukin-1β, interleukin-1β receptor, or interleukin 18 may be administered to a subject to treat VAAAD. | 04-07-2011 |
20110130349 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions - The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation. | 06-02-2011 |
20110160148 | Novel Diverse Lead Compound Autotaxin Inhibitors - Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well. | 06-30-2011 |
20110160149 | Pharmaceutical Composition for a Hepatitis C Viral Protease Inhibitor - Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants. | 06-30-2011 |
20110160150 | THIOL-CONTAINING COMPOUNDS FOR THE REMOVAL OF ELEMENTS FROM TISSUES AND FORMULATIONS THEREFOR - Methods and pharmaceutical formulations for ameliorating heavy metal toxicity and/or oxidative stress are disclosed, comprising administering pharmaceutically effective amounts of ligands according to the present disclosure. The ligands are of the general structure: | 06-30-2011 |
20110166085 | COMPOSITION COMPRISING CARBOHYDRATES AND PEPTIDES WHICH COMPRISE TRYPTOPHAN - An edible composition comprising peptides rich in tryptophan, which edible composition further comprises a rapidly available glucose composition and a slowly available glucose composition. | 07-07-2011 |
20110172171 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA - The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention of brain oedema. | 07-14-2011 |
20110183925 | ANTI-INFLAMMATORY PEPTIDE - Provided is an anti-inflammatory composition which has a high efficacy, causes no concern about side effects, is easy to ingest, and can also be administered for a long period of time because of its low cost and high safety. The present invention relates to a peptide comprising an amino acid sequence represented by pyroGlu-(X)n-A or a salt thereof, wherein X is independently Gln, Asn, or Pro; A represents Gln, Asn, Leu, Ile, Met, Val, or Phe; and n represents an integer of 0 to 2, and an anti-inflammatory composition comprising the same. | 07-28-2011 |
20110207679 | METHODS OF TREATMENT USING IL-16 ANTAGONIST PEPTIDES - The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases. | 08-25-2011 |
20110237525 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET - A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: | 09-29-2011 |
20110245188 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS - The present invention relates to methods and compositions of treating or preventing inflammatory diseases or conditions in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a glutathione donor, 5-amino 4-imidazolecarboxamide ribotide (AICAR), a 3-hydroxy-3-methylgluatryl-coenzymeA (HMG-CoA) reductase inhibitor, D-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol HCl (D-PDMP), and/or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (Miglustat), or derivatives thereof. | 10-06-2011 |
20110257107 | Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria - Disclosed are compounds containing single amino acids, peptides, or derivatives thereof which are selectively delivered to the mitochondria of a cell. Compounds of the invention exhibit antioxidant activity thereby reducing reactive oxygen species in cells. These compounds are useful for inhibiting oxidative stress-induced cell injury or death both in vivo and ex vivo. In addition, methods for the synthesis of these compounds are disclosed. | 10-20-2011 |
20110263516 | VASODILATOR - There is provided a vasodilator having an endothelium-dependent vasodilator effect, a prophylactic of arteriosclerosis, and functional food having an endothelium-dependent vasodilator effect, which is suitable for daily and regular intake and excellent in safety. The vasodilator and the functional food according to the present invention are characterized in at least one of the tripeptides Val-Pro-Pro and Ile-Pro-Pro, or a proteolytic product containing Val-Pro-Pro and/or Ile-Pro-Pro, contained as an active component. | 10-27-2011 |
20110301102 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention relates to specific treatment regimens for treating myelodysplastic syndrome. | 12-08-2011 |
20110319347 | ANTIOXIDANT AGENT - Disclosed is an antioxidant which can exhibit a higher antioxidant ability than known antioxidative peptides. The antioxidant according to the present invention comprises mimosine and/or a mimosine-containing peptide(s). The mimosine-containing peptide is a peptide which comprises at least one mimosine residue in its amino acid sequence. Mimosine has stronger antioxidant potency than known antioxidative tripeptides even when used as it is alone, and therefore is useful as an antioxidant. In addition, the antioxidant action of a peptide can be increased by introducing mimosine thereinto, thereby obtaining a peptide with higher antioxidant potency than the original one. | 12-29-2011 |
20120010158 | TUMOR NECROSIS FACTOR INHIBITING PEPTIDES AND USES THEREOF - The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders. | 01-12-2012 |
20120010159 | COMBINATION THERAPIES WITH COX-2 INHIBITORS AND TREPROSTINIL - The present invention is directed to compositions and methods for pain management, and for treating inflammation or an inflammation-associated disorder in a subject comprising administering to the subject a therapeutically effective amount of a COX-2 inhibitor and a therapeutically effective amount of a prostacyclin analog, such as treprostinil, a pharmaceutically acceptable salt thereof, or a treprostinil derivative described herein. | 01-12-2012 |
20120015892 | FORMULATIONS OF CANFOSFAMIDE AND THEIR PREPARATION - This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations. | 01-19-2012 |
20120058958 | Small Peptides And Methods For Blocking IgE Mediated Activation Of An Immune Cell - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of an immune cell, a method for stabilizing the cell membrane of an immune cell, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 03-08-2012 |
20120094938 | Small Peptides And Methods For Treatment Of Chronic Inflammatory Bowel Disease - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 04-19-2012 |
20120101049 | Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration - A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration. | 04-26-2012 |
20120101050 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-26-2012 |
20120142616 | Antineoplastic Hydrogels, and Enzyme-Instructed Preparations Thereof - Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of clinically-used therapeutics without compromising their bioactivities. In addition, the results disclosed herein demonstrate enzyme-instructed self-assembly as a facile strategy for generating the supramolecular hydrogels of molecules that inherently have poor solubility in water. For example, by covalently connecting paclitaxel with a motif that is prone to self-assemble, a hydrogel of paclitaxel can be formed without compromising the activity of the paclitaxel. | 06-07-2012 |
20120157394 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF - The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided. | 06-21-2012 |
20120157395 | ANTI-INFLAMMATORY AGENT FOR ORAL APPLICATION, AND ANTI-INFLAMMATORY PEPTIDE FOR ORAL APPLICATION - Disclosed are a composition having an anti-inflammatory function and a therapeutic method using the composition, both of which are effective for inflammatory diseases such as inflammatory bowel disease. Specifically disclosed are: an anti-inflammatory functional agent for oral application, which comprises a soybean peptide, wherein the soybean peptide contains fractions each having a molecular weight of 500 or less and excluding any free amino acid in an amount of 40 wt % or more and has a free amino acid content of 7 wt % or less; and a therapeutic method using the anti-inflammatory functional agent. More specifically disclosed are: a novel tripeptide which comprises the following amino acid sequence: phenylalanine-leucine-valine or valine-proline-tyrosine and has an anti-inflammatory function; an anti-inflammatory composition for oral application, a medicinal agent and a feed, each of which contains the novel tripeptide as an active ingredient; and a method for treating inflammatory bowel disease using the novel peptide. | 06-21-2012 |
20120165276 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 06-28-2012 |
20120270813 | Process for Preparing Peptide Products for Promoting Cholecystokinin Secretion and Use of the Peptide Products - A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof. | 10-25-2012 |
20120277167 | ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE - Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy. | 11-01-2012 |
20120295855 | METHODS FOR REDUCING OXIDATIVE STRESS IN A CELL WITH A SULFHYDRYL PROTECTED GLUTATHIONE PRODRUG - The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug. | 11-22-2012 |
20120329731 | THERAPEUTIC METHODS, COMPOSITIONS, AND COMPOUNDS - In one embodiment the invention provides a method of combating cyanide poisoning, which comprises administering to a subject a compound capable of releasing 3-mercapto-pyruvate in vivo. In other embodiments the invention also provides pharmaceutical compositions comprising a compound capable of releasing 3-mercaptopyruvate in vivo, as well as novel compounds that are capable of releasing 3-mercaptopyruvate in vivo. | 12-27-2012 |
20130035297 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 02-07-2013 |
20130040901 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY - The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide. | 02-14-2013 |
20130059799 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant. | 03-07-2013 |
20130109636 | TRI-AMINO RELEASING FULVATE | 05-02-2013 |
20130143826 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE - The present invention discloses chemical synthesis, anti-tumor and anti-metastatic effects of a dual functional conjugate as shown by formula I. Specifically, paclitaxel or docetaxol is linked with muramyl dipeptide derivative to form a conjugate, thus dual anti-tumor and anti-metastatic effects are achieved by combination of chemotherapy and immunotherapy. The present invention also discloses that paclitaxel or docetaxol and muramyl dipeptide derivative conjugate is synthesized by combination of solid-phase and solution-phase synthesis, and said conjugate can be used in manufacture of anti-tumor medicaments as proved by reliable bioassays. | 06-06-2013 |
20130165392 | HEPATOCYTE GROWTH FACTOR MIMICS AS THERAPEUTIC AGENTS - Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing. | 06-27-2013 |
20130184226 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS - The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity. | 07-18-2013 |
20130203687 | NOVEL LIPID TRIPEPTIDE-BASED HYDROGELATOR AND HYDROGEL - A hydrogel that includes an aqueous solution or an alcohol aqueous solution, and a hydrogelator containing a lipid peptide represented by Formula (1), or a pharmaceutically usable salt thereof. In Formula (1), R | 08-08-2013 |
20130217638 | Tubulysin Analogues - The present invention relates to novel tubulysin compounds (tubulysin analogues) as well as pharmaceutical formulations thereof. The present invention further relates to the use of such compounds for medicinal, agricultural, biotool or cosmetic applications. In particular, the novel tubulysin analogues show a cytostatic effect and can therefore be used for the treatment of proliferative disorders. The tertiary amide moiety of the tubulysin analogues (so-called tubugis) according to the present invention is generated by an Ugi-type reaction. | 08-22-2013 |
20130244957 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 09-19-2013 |
20130252907 | Small Peptides And Methods For Blocking IgE Mediated Activation Of An Immune Cell - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of an immune cell, a method for stabilizing the cell membrane of an immune cell, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-26-2013 |
20130274208 | Small Peptides And Methods For Treatment Of Chronic Inflammatory Bowel Disease - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 10-17-2013 |
20130281385 | SMALL MOLECULE APOPTOSIS PROMOTERS - The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 10-24-2013 |
20130303465 | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors - This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. | 11-14-2013 |
20130303466 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention. | 11-14-2013 |
20130345155 | MODULATORS FOR SIRT6 AND ASSAYS FOR SCREENING SAME - Method for identifying a modulator of Sirt6, PfSir2a, or Sirt7 deacylase activity, wherein a fatty-acylated substrate containing an acyl-lysine moiety and an indicator moiety is contacted with Sirt6, PfSir2a, or Sirt7 in the presence of a candidate compound under conditions for Sirt6, PfSir2a, or Sirt7 to deacylate the substrate, wherein the acyl is a hydrophobic fatty acyl group containing a hydrocarbon group having at least three carbon atoms connected by carbon-carbon bonds; contacting the deacylated substrate with a cleavage agent that cleaves the linkage between the lysine and indicator moiety to generate a detectable signal; and correlating a quantified Sirt6, PfSir2a, or Sirt7 deacylase activity therefrom. Modulating compounds of Sirt6, PfSir2a, or Sirt7 deacylase activity are also described, as are pharmaceutical compositions thereof, methods of treatment by administration of the modulating compounds, and kits for practicing the method. | 12-26-2013 |
20140142050 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES - The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions. | 05-22-2014 |
20140256654 | BIFUNCTIONAL COMPOUNDS - A compound having the formula: | 09-11-2014 |
20140288012 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS - The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury. | 09-25-2014 |
20140303095 | Novel Peptidomimetics And Their Application - Novel peptidomimetics exhibiting affinity for opioid receptors, possessing general formula show on FIG. | 10-09-2014 |
20140336134 | IAP BIR Domain Binding Compounds - A compound of Formula I | 11-13-2014 |
20140357579 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF - The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 12-04-2014 |
20140378396 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, apoptosis inhibition and electrical conductance. | 12-25-2014 |
20150025023 | CYCLODEXTRIN - The invention provides a method for preparing sulphoalkyl ether-β-cyclodextrin. The method comprises first contacting cyclodextrin with a base to form activated cyclodextrin. The method then comprises separately contacting the activated cyclodextrin with an alkyl sultone to form sulphoalkyl ether-β-cyclodextrin. The activation reaction is carried in batch and the sulphoalkylation reaction is carried out under continuous flow conditions. | 01-22-2015 |
20150025024 | Solid Compositions - The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 01-22-2015 |
20150045311 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME - The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride. | 02-12-2015 |
20150051160 | TYROSINE BASED LINKERS FOR THE RELEASABLE CONNECTION OF PEPTIDES - The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases. | 02-19-2015 |
20150065437 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant. | 03-05-2015 |
20150072942 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES - Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses. | 03-12-2015 |
20150087605 | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules - Disclosed are compositions and methods for treating anthrax, inhibiting anthrax toxins and inhibiting anthrax toxin-induced cytotoxicity. Carboxylic acid-containing small molecules can be used in the methods and compositions disclosed herein, for example, sulindac and derivatives thereof may be used. Methods of screening for carboxylic acid-containing small molecules that can be used to treat anthrax are disclosed. Targeting the anthrax toxin reduces the risks of anthrax spores. | 03-26-2015 |
20150099709 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA - The present invention relates to a use of a compound having ghrelin receptor agonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for treatment of diseases including achlorhydria in which abnormal gastric acid secretion is involved. In addition, the present invention relates to the method of treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agents. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound of the present invention or a pharmaceutically acceptable salt thereof for the treatment of said diseases. | 04-09-2015 |
20150111838 | CYCLODEXTRIN COMPLEXATION METHODS FOR FORMULATING PEPTIDE PROTEASOME INHIBITORS - This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. As well as cyclodextrin complexation methods of formulating a peptide proteasome inhibitor (e.g., a compound of formula (1)-(5) or a pharmaceutically acceptable salt thereof) with one or more cyclodextrins. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. For example, homogenous solutions of a compound of formula (5) (carfilzomib) can be obtained at a pharmaceutically useful pH (e.g., about 3.5) and at higher concentrations (e.g., about 5 mg/mL) than could be obtained without one or more cyclodextrins and the processes of complexation between the compound and one or more cyclodextrins provided herein. | 04-23-2015 |
20150119342 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers - The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients. | 04-30-2015 |
20150133394 | Compositions And Methods For Increasing Carnitine Level In Muscle Tissue - Compositions and methods utilizing thiol-containing short peptides having the sequence Cys-Lys-Met-Cys (SEQ ID NO: 1) and optionally N- and C-terminal modifications for increasing carnitine level in muscle tissues, and treating or preventing diseases or disorders affecting muscle tissue. | 05-14-2015 |
20150141351 | Solid Pharmaceutical Compositions - The present invention features solid pharmaceutical compositions comprising Compound 1 (or a pharmaceutically acceptable salt thereof), Compound 2 (or a pharmaceutically acceptable salt thereof), and ritonavir (a pharmaceutically acceptable salt thereof), which are co-formulated in amorphous solid dispersion comprising a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant. | 05-21-2015 |
20150291659 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF - Solomanamide analogues of Formula-I having anti-inflammatory activity, and viable synthetic routes for the preparation of such analogues, including the synthesis of macrocyclic core of Salomanamide analogues. The Solomanamide analogues of Formula-I or their pharmaceutical salt may be provided in a pharmaceutical composition and administered in an effective amount for the treatment of inflammation and/or pain. | 10-15-2015 |
20150307835 | PEPTIDES COMPRISING A SHORT-CHAIN POLYETHYLENE GLYCOL MOIETY - Described are compounds comprising a peptide moiety linked through a linkage to a short-chain polyethylene glycol moiety, more particularly compounds wherein the peptide moiety comprises a self-assembling peptide sequence, and compositions and hydrogels comprising these compounds. Further, methods for the preparation of the present compounds comprising a peptide moiety linked through a linkage to a short-chain polyethylene glycol moiety are disclosed. | 10-29-2015 |
20150359838 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 12-17-2015 |
20150368294 | GADD45BETA TARGETING AGENTS - Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders. | 12-24-2015 |
20150374606 | TETRAPEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT - A tetrapeptide having antioxidant activity is provided. The tetrapeptide has a structure comprising, in amino acid sequence from N-terminus to C-terminus: tryptophan-X-tyrosine-X; wherein X is arginine, lysine, histidine or any positively-charged amino acid derivative such as 5-hydroxylysine, ornithine, 2,4-diamino-butyrate and 2,3-diamino-propionate. Each amino acid of the sequence or its Homo-amino acid derivative is independently of the D configuration (D-stereoisomer) or of the L configuration (L-stereoisomer), and the C-terminal comprises one selected from the group consisting of carboxyl (—COOH), and carboxamide (—CONH | 12-31-2015 |
20150376234 | SHORT PEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT - A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group. A method to prepare a composition having antioxidant activity and a composition having antioxidant activity are also provided. | 12-31-2015 |
20160058826 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY - The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide. | 03-03-2016 |
20160083422 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS - Granzyme B inhibitor compounds, compositions that include the compounds, and methods for using the compounds. The compounds of the invention have advantageous water solubility and effectively inhibit Granzyme B. | 03-24-2016 |
20160137692 | TARGETED NITROXIDE AGENTS - Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. | 05-19-2016 |
20160143985 | ICE-CLEAVED ALPHA-SYNUCLEIN AS A BIOMARKER - The present disclosure provides ICE-cleaved alpha-synuclein fragments as biomarkers for alpha-synuclein-associated disease or disorder and/or for ICE-regulator therapy. | 05-26-2016 |
20160151443 | METHOD FOR MEDICAL TREATMENT UTILIZING GLUTATHIONE | 06-02-2016 |
20160158309 | EXERCISE FUNCTION ENHANCER - The inventors of the present invention have discovered that glutathione inhibits reduction in muscle pH, and activates PGC-1α to increase production of mitochondrial DNA. The present invention has been completed based on these findings. | 06-09-2016 |
20160176836 | BIFUNCTIONAL COMPOUNDS | 06-23-2016 |
20160376309 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant. | 12-29-2016 |
20190142893 | Electron, Radical, or Reactive Oxygen Species-Scavenging Agent Based Therapy of Inborn Errors of Fatty Acid Oxidation and Oxidative Phosphorylation | 05-16-2019 |